Experience of pharmacological cardioversion with refralon in persistent atrial fibrillation and flutter according to the data of the cardiology department of Orenburg regional clinical hospital

Aim. To assess the effectiveness and safety of refralon based cardioversion on the experience of the cardiology department of Orenburg Regional Clinical Hospital.

Methods. The archival medical histories of 14 patients with persistent atrial fibrillation (AF) and 2 patients with persistent atrial flutter (AFL) (overall 16 patients), who underwent an attempt to restore sinus rhythm with refralon, were analyzed. The mean age of the patients was 51.7±10.4 years. The mean duration of AF/AFL since its last detection was 8.0±6.5 weeks (from 8 days to 8 months). Fifteen patients had hypertension, 3 of them had coronary artery disease (CAD), and 1 patient had CAD with type 2 diabetes mellitus. One of the patients had lone AF. Before cardioversion, all patients underwent the following examination: clinical and biochemical blood tests, clinical urine tests, electrocardiography (ECG), echocardiography (Echo), transesophageal Echo, Holter ECG, the determination of the level of thyroid-stimulating hormone, thyroxine, electrolytes, including potassium and magnesium.

Results. According to Echo, initially, the transverse size of the left atrium in patients was 4.3±0.3 cm. Its increase was noted in 68.7% of patients (from 4.3 to 5.0 cm). Restoration of sinus rhythm after the first step of refralon administration at a dose of 10 μg/kg was achieved in 8 patients, after the second step of administration (total dose 20 μg/kg) - in 5 patients and after the third step (total dose 30 μg/kg) - in 2 patients. In 1 patient, restoration of sinus rhythm was not achieved after the administration of the third bolus. Out of 15 patients with restored sinus rhythm, AF recurrence occurred in three. In one of the patients with successful cardioversion, the sinus rhythm was restored the next day. The duration of the last episode of AF and the size of the left atrium did not significantly affect the effectiveness of cardioversion and amounted to 62±54 days and 4.3±0.35 cm, respectively, in patients with successful cardioversion, and with a recurrence of AF - 34.3±28 days and 4.2±0.35 cm (p=0.2; р=0.6). The efficacy of cardioversion with refralon was 71.4% in patients with AF, and 100% in patients with AFL. No adverse events of refralon were found in patients.

Conclusion. At the time of discharge, sinus rhythm was recorded in 12 out of 16 patients (75%). The ineffectiveness of cardioversion with refralon was noted only in patients with AF; in all patients with AFL the sinus rhythm was restored.

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8): 837-47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.

2. Pistoia F, Sacco S, Tiseo C, et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. 2016;34(2): 255-68. https://doi.org/10.1016/j.ccl.2015.12.002.

3. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373(9658): 155-66. https://doi.org/10.1016/ S0140-6736(09)60040-4.

4. Kalinin RE, Suchkov IA, Boguto ON. Embolism of main arteries in atrial fibrillation. I.P.Pavlov Russian medical biological herald. 2012;2: 236-42. (In Russ.). https://doi.org/10.17816/PAVLOVJ20122234-241.

5. Bekwelem W, Connolly SJ, Halperin JL, et al. Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes. Circulation. 2015;132: 787-89. https://doi.org/10.1161/circulationaha.114.013243.

6. Clinical recommendations of the Russian Society of Cardiology “Atrial fibrillation and flutter in adults”. Мoscow:2020. Available from http://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf

7. Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86: 516-21. https:// doi.org/10.1136/heart.86.5.516.

8. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370-75. https://doi.org/10.1001/ jama.285.18.2370.

9. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of artrial fibrillation: Global Burden of Disease 2010 study. Circulation. 2014;129 (8): 837-47. https://doi.org/10/1161/CIRCULATIONAHA.113/005119.

10. Doschitsin VL, Fedorova MH. Treatment of atrial fibrillation in comorbid patients of the senior age. Consilium medicum. 2018;20(12): 47-54 (In Russ.). https://doi.org/10.26442/20751753.2018.12.180156

11. Vostrikov VA, Razumov KV. Efficiency of Electrical Cardioversion of Paroxysmal Atrial Fibrillation in the Use of Bipolar QuasiSinusoidal Impulse in Patients with Coronary Heart Disease. General reanimatology. 2014;10(2): 41-49 (In Russ.). https://doi.org/org/10.15360/1813-9779-2014-2-41-49.

12. Van Gelder IC, Crijns HJ, Van Glist WH et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68: 41-46. https://doi.org/10.1016/0002-9149(91)90707-r

13. Vostrikov VA. Cardioversion of atrial and ventricular tachyarrhythmias. In. Guide to cardiac arrhythmias (Ed. Chazov EI, Golitsyn SP). Moscow: GEOTAR Media 2008: 245-272. (In Russ.).

14. Yuricheva YuA, Sokolov SF, Golitsyn SP et al. A novel III class antiarrithmic, niferidil, as an effective medication for the sinus rhythm recovery in patients with persistent atrial fibrillation. Journal of Arrhythmology. 2012;70: 32-43. (In Russ.).

15. Bregvadze I, Maykov E, Sokolov S, et al. The predictors of the efficacy of pharmacological cardioversion with class III antiarrhythmic drug - nibentan in patients with persistent atrial fibrillation. Eur Heart J 2017;8: 1374. https://doi.org/10.1093/eurheartj/ehx493.P6383.

16. Eremeev AG. Modern antiarrhythmic drugs. What is the clinician’s choice? Young Scientist. 2018;46(232): 80-86. (In Russ.).

17. Bregvadze IN, Maikov E B, Bildinov OA, et al. Efficacy and safety of nibentan in drug-induced cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose restriction and the use of magnesium sulfate. Cardiology 2007;3: 48-55. (In Russ.).

18. Galperin J, Elizari MV, Chiale PA, et al. Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts longterm sinus rhythm maintenance. J Cardiovasc Pharmacol Ther. 2003;8: 179-86. https://doi.org/10.1177/107424840300800302.

19. Rosenshtraukh LV, Fedorov VV, Reznik AV, et al. Electrofhisiological experimental study of a novel class III antiarrhythmic drug RG-2. Cardiology. 2003;9: 56-64. (In Russ.).

20. Juricheva JuA, Maikov EB, Sokolov SF, Klimenko UL, et al. The first clinical experience with a new antiarrhythmic drug class III niferidil in patients with persistent atrial fibrillation. J Cardiol., 2011;1: 55-64. (In Russ.).

21. Maykov EB, Yuricheva YuA, Mironov NYu, Sokolov SF. Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter. Terapevticheskii arkhiv. 2015;1: 38-48. (In Russ.). https://doi.org/10.17116/terarkh201587138-48.

22. Gromyko TY, Sayganov SA. Remodelling of the left atrial at the patients with atrial fibrillation in various methods of sinus rhythm recovery. Herald of the Northwestern State Medical University named after I.I. Mechnikov. 2017;9(2): 51-59. (In Russ.). https://doi.org/10.17816/mechnikov20179251-59.

23. Vlodzyanovskiy VV, Malkina TA, Sokolov SF et al. Restoration of sinus rhythm in patients with persistent atrial fibrillation and obesity: new possibilities of pharmacological cardioversion. J Cardiol. 2017;57(10): 80-86. (In Russ.). https://doi.org/10.18087/ cardio.2017.10.10036.